News

Immune therapy continues to advance in NSCLC

Publish date: March 28, 2014

 

AT THE NCCN ANNUAL CONFERENCE

Dr. Horn reported receiving grant or research support from Astellas Pharma, and consulting fees or honoraria from Boehringer Ingelheim. She has served as a scientific adviser for Bristol-Myers Squibb, Helix BioPharma, and Puma Biotechnology.

Pages

Recommended Reading

Synthetic lethality: beating cancer at its own game
MDedge Hematology and Oncology
Lung cancer screening strategy a work in progress
MDedge Hematology and Oncology
Compounds in exhaled breath could improve high-risk lung cancer screening
MDedge Hematology and Oncology
Meaningful use criteria bolster lung cancer screening program
MDedge Hematology and Oncology
Prior resection poses certain risks in lung transplantation
MDedge Hematology and Oncology
Hormone therapy predicted improved lung cancer survival in women
MDedge Hematology and Oncology
The push for smaller, smarter cancer trials
MDedge Hematology and Oncology
Amrubicin combination fails in phase III trial
MDedge Hematology and Oncology
Biomarker unreliability scratches trial of customized chemotherapy
MDedge Hematology and Oncology
Ceritinib found safe and effective for NSCLC
MDedge Hematology and Oncology